Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Berlin - Delayed Quote EUR

Terns Pharmaceuticals Inc (430.BE)

Compare

3.6000

+0.0400

+(1.12%)

As of 12:12:07 PM GMT+1. Market Open.

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 24, 2025 an equity inducement award to Andrew Gengos, the Company’s new chief financial officer, under the terms of the 2022 Employment Inducement Award Plan,

GlobeNewswire 14 hours ago

TERN
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ongoing U.S. healthy volunteer PK study shows improved drug-drug interaction profile compared to asciminib Introduces TERN-601 Phase 2 FALCON obesity study design; on track to initiate study in early 2Q25 with 12-week data expected 2H25 Cash and cash equivalents expected to provide runway into 2028 FOSTER CITY, Calif., Feb. 25, 2025 (GLOBE

GlobeNewswire yesterday

TERN
Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.

Pharma Voice 2 days ago

TERN
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Seasoned public company CFO with 25 years of leadership experience in biotechFOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. “We are delighted to have Andrew

GlobeNewswire 2 days ago

TERN
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertiseFOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Compa

GlobeNewswire 6 days ago

TERN
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:00 p.m. ET. A li

GlobeNewswire 21 days ago

TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equi

GlobeNewswire 23 days ago

TERN
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025 at 4:30 p.m. PT. A live webcast of the presentation will be available on the investor rela

GlobeNewswire last month

TERN
Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Terns Pharmaceuticals, Inc. (NASDAQ:TERN) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at […]

Insider Monkey 2 months ago

TERN
Terns Pharmaceuticals CEO & Director Acquires 423% More Stock

Potential Terns Pharmaceuticals, Inc. ( NASDAQ:TERN ) shareholders may wish to note that the CEO & Director, Amy...

Simply Wall St. 2 months ago

TERN
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts High levels of target coverage achieved with once daily dosing at all doses Completion of dose escalation and initiation of dose expansion expected in 1H25 Additional efficacy data expected in 4Q

GlobeNewswire 2 months ago

TERN
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experienceFOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc.

GlobeNewswire 3 months ago

TERN
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 3 months ago

TERN
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early December 2024 Plans to initiate Phase 2 clinical trial for TERN-601 in obesity in early 2Q25 with initial 12-week data expected in 2H25 Cash, cash equivalents and marketable securities of $372.8 million, including $172.7 million equity raise in September, expected to provide runway into 2028 FOSTER CITY,

GlobeNewswire 3 months ago

TERN
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in November. UBS Global Healthcare ConferenceFormat: Fireside Chat Date and Time: Wednesday

GlobeNewswire 3 months ago

TERN
Insiders Snap Up These 2 ‘Strong Buy’ Stocks

Let’s talk about insider trading. Not the illegal kind, but the perfectly normal – and fully legal – trading by top-level corporate officers. These are the C-suite residents and the members of the Boards, company officers who know what’s going on behind the scenes and are responsible to shareholders for bringing in profits. They typically hold shares in their own companies and make trades based on the knowledge they have from behind the scenes. To keep the playing field level, federal regulators

TipRanks 5 months ago

PR

TERN
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

Motley Fool 5 months ago

TERN

NVO

LLY
OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc

On September 12, 2024, OrbiMed Advisors LLC, a prominent investment firm, executed a significant transaction by acquiring an additional 6,807,336 shares of Terns Pharmaceuticals Inc (NASDAQ:TERN). This purchase was made at a price of $9.51 per share, reflecting a strategic move by the firm to bolster its position in the biotechnology sector. Following this transaction, OrbiMed Advisors now holds a total of 7,562,971 shares in Terns Pharmaceuticals, marking a substantial increase in its investment portfolio.

GuruFocus.com 5 months ago

TERN
With 55% ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) boasts of strong institutional backing

Key Insights Institutions' substantial holdings in Terns Pharmaceuticals implies that they have significant influence...

Simply Wall St. 5 months ago

TERN
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.

Terns Pharmaceuticals just proved that it's competitive in the weight loss field.

Motley Fool 5 months ago

VKTX

TERN

Performance Overview

Return	430.BE	S&P 500
YTD	-34.55%	+1.27%
1-Year	-50.82%	+17.29%
3-Year	-26.53%	+35.84%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Terns Pharmaceuticals Inc (430.BE)

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Terns Pharmaceuticals CEO & Director Acquires 423% More Stock

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

Insiders Snap Up These 2 ‘Strong Buy’ Stocks

This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments

OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc

With 55% ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) boasts of strong institutional backing

Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.

Performance Overview